Phase Ii Trial Of A Novel Immunotherapy Combination Of Pembrolizumab And Her2 Bi-Armed Activated T Cells (Bats) In Metastatic Castrate Resistant Prostate Cancer

Meera Patel,Lawrence G. Lum,Abhinav Deol,Archana Thakur,Elisabeth I. Heath,Wei Chen,Kimberlee Dobson,Joseph A. Fontana,Ulka N. Vaishampayan

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 6|浏览49

暂无评分

摘要

97Background: Immune checkpoint inhibitors (ICI) have demonstrated only modest efficacy in metastatic castrate resistant prostate cancer (mCRPC). Anti-HER2 and Anti-CD3 bispecific antibody armed ac...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要